Brief Report: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living With HIV
This nested pharmacokinetic sub-study shows that children weighing 14-24.9 kg and >25 kg taking ATV/r 200/75 mg and 300/100 mg respectively, achieve concentrations comparable to those that are safe and effective in adults.
Authors
- Veronica Mulenga (ORCID: https://orcid.org/0000-0003-1843-8169)
- Alexander J. Szubert (ORCID: https://orcid.org/0000-0002-2082-0861)
- David Burger
- Chishala Chabala (ORCID: https://orcid.org/0000-0002-5551-5752)
- Hylke Waalewijn (ORCID: https://orcid.org/0000-0002-5135-8729)
- Alasdair Bamford (ORCID: https://orcid.org/0000-0003-4764-229X)
- Victor Musiime (ORCID: https://orcid.org/0000-0001-7472-9054)
- Anne E. M. Kamphuis (ORCID: https://orcid.org/0000-0002-6452-7827)
- Diana M. Gibb (ORCID: https://orcid.org/0000-0002-9738-5490)
- Shafic Makumbi (ORCID: https://orcid.org/0009-0009-2284-9017)
- Vivian Mumbiro
- Angela Colbers (ORCID: https://orcid.org/0000-0002-0389-9934)
- Saskia N. de Wildt (ORCID: https://orcid.org/0000-0002-0502-0647)
- Mutsa Bwakura‐Dangarembizi (ORCID: https://orcid.org/0000-0001-7751-6177)
- Roeland E. Wasmann (ORCID: https://orcid.org/0000-0002-5769-8150)
- Joan Nangiya
Institutions
- Radboud University Nijmegen (NL)
- University of Zimbabwe (ZW)
- University of Cape Town (ZA)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- University Teaching Hospital (ZM)
- Radboud University Medical Center (NL)
- University of Zambia (ZM)
- MRC Clinical Trials Unit at UCL (GB)
- Radboud Institute for Molecular Life Sciences (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Joint Clinical Research Centre (UG)
- University College London (GB)
- Makerere University (UG)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1097/qai.0000000000003704
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Pfizer
- Gilead Sciences
- ViiV Healthcare
- University College London
- Medical Research Council
- Janssen Pharmaceuticals
- European and Developing Countries Clinical Trials Partnership